Does the Type of Ventricular Assisted Device Influence Survival, Infection, and Rejection Rates Following Heart Transplantation?
- 1 May 2009
- journal article
- research article
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 24 (3) , 250-255
Abstract
To determine the influence of the type of left ventricular assisted device (LVAD) as predictor of survival, hospitalizations due to infection, and rejection following heart transplantation and to delineate any further predictors of such outcomes. Patients who received a left ventricular assist device (HeartMate [Thoratec Corp., Pleasanton, CA, USA] or Novacor [World Heart Corporation, Ottawa, Canada]) as a bridge to heart transplantation between October 1991 and June 2004 using the United Network for Organ Sharing (UNOS) Thoracic Registry database were evaluated. Comparison of survival curves between HeartMate and Novacor was performed using Kaplan-Meier survival method and Cox proportional hazard model adjusting for patient demographics and co-morbidities. Infection and rejection rates between the two devices were analyzed using multivariable logistic regression model. The UNOS database provided 1255 patients with HeartMate and 154 patients with Novacor between 1991 and 2004. Unadjusted one- and five-year survivals for HeartMate and Novacor were 0.84 and 0.80 and 0.72 and 0.56, respectively, following heart transplantation. Adjusting for patient demographics and co-morbidities, no statistical significant difference in one-year survival was observed between those who received HeartMate and Novacor (HR = 1.49, p = 0.127). At five years, however, the HeartMate group had higher survival than Novacor (HR = 1.53, p = 0.043). All-time posttransplant hospitalizations due to infection and rejection were similar between HeartMate and Novacor recipients after adjusting for patient case mix. Controlling for patient case mix, there was no survival difference at one year between those who received Novacor versus HeartMate LVAD. At five years, a Novacor bridge to transplant patient on average had statistically significantly lower survival than HeartMate recipients. No difference in infection and rejection were observed.Keywords
This publication has 15 references indexed in Scilit:
- Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Heart Transplant Report—2005The Journal of Heart and Lung Transplantation, 2005
- Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experienceThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Ventricular Assist Devices as a Bridge to Cardiac Transplantation: The Ottawa ExperienceArtificial Organs, 2004
- Left Ventricular Assist Devices as Bridge to Heart Transplantation: The Niguarda ExperienceJournal of Cardiac Surgery, 2003
- Treatment of end-stage heart disease with outpatient ventricular assist devicesThe Annals of Thoracic Surgery, 2002
- Left ventricular assist device therapy improves utilization of donor heartsJACC, 2002
- Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Clinical Experience With Long-Term Use of Implantable Left Ventricular Assist Devices: Indications, Implantation, and OutcomesSeminars in Thoracic and Cardiovascular Surgery, 2000
- Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome?The Journal of Thoracic and Cardiovascular Surgery, 1996
- Cardiac transplantation after mechanical circulatory support: A Canadian perspectiveThe Annals of Thoracic Surgery, 1996